These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When ...

Research by UMass Chan Medical School scientists Sharon Cantor, Ph.D., and Jenna M. Whalen, Ph.D., poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 tumor cells.

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

However, drug resistance remains a major challenge in PARPi therapy, with the majority of patients eventually experiencing ...